Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00

Pharvaris (NASDAQ:PHVS) had its price objective hoisted by JMP Securities from $46.00 to $55.00 in a research note released on Friday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

Pharvaris Trading Down 0.7 %

Shares of NASDAQ:PHVS opened at $17.60 on Friday. Pharvaris has a 1 year low of $15.21 and a 1 year high of $33.00. The firm has a fifty day moving average price of $19.02 and a 200 day moving average price of $19.35.

Hedge Funds Weigh In On Pharvaris

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio bought a new position in shares of Pharvaris in the third quarter worth about $57,000. Barclays PLC bought a new position in Pharvaris in the 3rd quarter worth approximately $106,000. Geode Capital Management LLC increased its position in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after buying an additional 5,753 shares during the period. HighVista Strategies LLC lifted its holdings in shares of Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after buying an additional 6,018 shares during the last quarter. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Pharvaris in the fourth quarter worth $196,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.